News in lipid lowering treatment

Česká verzia

Authors: Michal Vrablík; Richard Češka
Authors place of work: Centrum preventivní kardiologie III. interní kliniky 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in the journal: Vnitř Lék 2014; 60(11): 949-957
Category: Reviews

Summary

Options for modification of lipoprotein metabolism and, thus, for reduction of atherothrombotic complication have widened over recent years. Apart from the development of novel approaches new pharmacological formulations of common lipid lowering drugs have been prepared- e.g. statin-containing nanoparticles, fibrate nanoparticles with a much higher bioavailability etc. Even the oldest lipid lowering agents – resins – have not been forgotten due to its once again discovered positive impact of these agents on glucose homeostasis while optimally complementing the action of statins. Clinical trials of therapies targeting HDL particle metabolism are being in progress despite we have not gathered any unambiguous evidence of positive effect of the CETP inhibitors or apoA1 mimetics on the progression of atherosclerosis. Brand new approaches in the treatment of dyslipidemia including MTTP and PCSK9 inhibition or therapies utilizing anti-sense technologies rapidly accumulate evidence from clinical studies. We have already learned about their lipid-modifying efficacy particularly in patients with familial hypercholesterolemia, however, data from other patients´ populations can be expected quite soon.

Key words:
CETP inhibitors – dyslipidemia – ezetimibe – fibrates – lomitapid – mipomersen – PCSK9 inhibitors – statins – resins

Zdroje

1. Gardner CD, Kiazand A, Alhassan S et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA 2007; 297(9): 969–977.

2. Catapano AL, Reiner Z, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217(1): 3–46.

3. Keith M, Kuliszewski MA, Liao C et al. A modified portfolio diet complements medical management to reduce cardiovascular risk factors in diabetic patients with coronary artery disease. Clin Nutr 2014; pii: S0261–5614(14)00174–00175. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clnu.2014.06.010>.

4. Vrablík M. Hypolipidemika, jak je neznáte. Hypertenze a KV prevence 2013; 2: 53–57.

5. Estruch R, Ros E, Salas-Salvadó J. PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368(14): 1279–1290.

6. Borberg H. The lower the better: target values after LDL-Apheresis and semi-selective LDL-elimination therapies. Transfus Apher Sci 2013; 48(2): 203–206.

7. Khan TZ, Pottle A, Pennell DJ et al. The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina. Glob Cardiol Sci Pract 2014(1): 3–12.

8. McGowan MP. Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol – the role of LDL-apheresis. J Clin Lipidol 2013; 7(3 Suppl): S21-S26.

9. Ginsberg HN, Elam MB, Lovato LC et al. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1563–1574.

10. Cha KH, Cho KJ, Kim MS et al. Enhancement of the dissolution rate and bioavailability of fenofibrate by a melt-adsorption method using supercritical carbon dioxide. Int J Nanomedicine 2012; 7: 5565–5575.

11. Chew EY, Ambrosius WT, Davis MD. ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetess. N Engl J Med 2010; 363(3): 233–244.

12. Duivenvoorden R, Tang J, Cormode DP et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat Commun 2014, 5: 3065. Dostupné z DOI: <http://doi: 10.1038/ncomms4065>.

13. Califf RM, Lokhnygina Y, Cannon CP et al. An update on the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J 2010; 159(5): 705–709.

14. Temel RE, Brown MJ. Biliary and non-biliary contributions to reverse cholesterol transport . Curr Opin Lipidol 2012; 23(2): 85–90.

15. Chiang JY. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev 2002; 23(4): 443–463.

16. Bays HE, Goldberg RB, Truitt KE et al. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008; 168(18): 1975–1983.

17. Tall AR. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med 2007; 356(13): 1364–1366.

18. Joy TR, Hegele RA. The failure of torcetrapib: what have we learned? Br J Pharmacol 2008; 154(7): 1379–1381.

19. Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357(21): 2109–2122.

20. Schwartz GG, Olsson AG, Abt M et al. OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367(22): 2089–2099.

21. Nissen S, Tardif JC, Nicholls SJ et al. Effects of torcetrapib on progression of coronary atherosclerosis. N Engl J Med 2007; 356(13): 1304–1316.

22. Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290(17): 2292–2300.

23. Tardif JC, Ballantyne CM, Barter P et al. Can Hdl Infusions Significantly QUicken Atherosclerosis REgression (CHI-SQUARE) Investigators. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J 2014. Přijato do tisku 2014.

24. Cuchel M, Bloedon LT, Szapary PO et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007; 356(2): 148–156.

25. Sacks FM, Stanesa M, Hegele RA. Severe hypertriglyceridemia with pancreatitis: thirteen years’ treatment with lomitapide. JAMA Intern Med 2014; 174(3): 443–447.

26. Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther 2013, 35(8): 1082–1098.

27. Bryant LM, Christopher DM, Giles AR et al. Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev 2013; 24(2): 55–64.

28. Kastelein JJ, Wedel MK, Baker BF et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114(16): 1729–1735.

29. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009; 50(Suppl): S172-S177.

30. Cohen CJ, Boerwinkle E, Mosley TH et al. Sequence variations in PCSK9, low LDL and protection against coronary heart disease. N Engl J Med 2006; 354(12): 1264–1272.

31. Stein EA, Mellis S, Yancopoulos GD et al. Effect of monoclonal antibody to PCSK9 on plasma LDL cholesterol. N Engl J Med 2012; 366(12): 1108–1118.

32. Stein EA, Wasserman SM, Dias C et al. AMG-145. Drugs of the Future 2013; 38(7): 451–459.

33. Reichert JM. Antibodies to watch in 2014. MAbs 2014; 6(1): 5–14.